Recent genomic studies in lung adenocarcinoma have identified other potential therapeutic targets, such as mutations in KRAS, HER2 and BRAF, ROS1 rearrangements, RET fusions and MET amplification [17,18]. The gene discussed is RET; the disease is lung adenocarcinoma.